Skip Navigation
ChemIDplus A TOXNET DATABASE LiteBrowseAdvanced

Substance Name: Vindesine sulfate [USAN:JAN]
RN: 59917-39-4
UNII: CPH2U7DNDY
InChIKey: COFJBSXICYYSKG-OAUVCNBTSA-N

Note

  • Vinblastine derivative with antineoplastic activity against CANCER. Major side effects are myelosuppression and neurotoxicity. Vindesine is used extensively in chemotherapy protocols (ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS).

Molecular Formula

  • C43-H55-N5-O7.H2-O4-S

Molecular Weight

  • 852.0133
 

Classification Codes

  • Antineoplastic
  • Drug / Therapeutic Agent
  • Mutation Data
  • Reproductive Effect
* denotes mobile formatted website

Links to Resources


Search for this InChIKey on the Web

Names and Synonyms

Name of Substance

  • Vindesine sulfate [USAN:JAN]

Synonyms

  • 23-Amino-O(sup 4)-deacetyl-23-demethoxyvincaleukoblastine sulfate
  • 3-Carbamoyl-4-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine sulfate (1:1) (salt)
  • 4-Desacetilvinblastina-C-3-carboxamida sulfato
  • 4-Desacetilvinblastina-C-3-carboxamida sulfato [Spanish]
  • DAVA
  • Desacetylvinblastine amide sulfate
  • EINECS 261-984-7
  • Eldesine
  • Eldisine
  • Lilly 99094
  • LY 099094
  • LY099094
  • NSC 245467
  • UNII-CPH2U7DNDY
  • Vincaleukoblastine, 23-amino-O(sup 4)-deacetyl-23-demethoxy-, sulfate
  • Vincaleukoblastine, 3-(aminocarbonyl)-O(sup 4)-deacetyl-3-de(methoxycarbonyl)sulfate (1:1) (salt)
  • Vindesina sulfato
  • Vindesina sulfato [Spanish]
  • Vindesine sulfate

Systematic Names

  • Vincaleukoblastine, 3-(aminocarbonyl)-O(sup 4)-deacetyl-3-de(methoxycarbonyl)-, sulfate (1:1) (salt)
  • Vincaleukoblastine, 3-(aminocarbonyl)-O4-deacetyl-3-de(methoxycarbonyl)-, sulfate (1:1) (salt)

Registry Numbers

CAS Registry Number

  • 59917-39-4

FDA UNII

  • CPH2U7DNDY

System Generated Number

  • 0059917394

Molecular Formulas

Molecular Formula

  • C43-H55-N5-O7.H2-O4-S

Molecular Formula Fragments

  • C43-H55-N5-O7
  • COMPONENT
  • H2-O4-S

Structure Descriptors

InChI

1S/C43H55N5O7.H2O4S/c1-6-39(52)21-25-22-42(38(51)55-5,33-27(13-17-47(23-25)24-39)26-11-8-9-12-30(26)45-33)29-19-28-31(20-32(29)54-4)46(3)35-41(28)15-18-48-16-10-14-40(7-2,34(41)48)36(49)43(35,53)37(44)50;1-5(2,3)4/h8-12,14,19-20,25,34-36,45,49,52-53H,6-7,13,15-18,21-24H2,1-5H3,(H2,44,50);(H2,1,2,3,4)/t25-,34-,35+,36+,39-,40+,41+,42-,43-;/m0./s1

InChIKey

COFJBSXICYYSKG-OAUVCNBTSA-N

Smiles

CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C2)(C(=O)OC)c5cc6c(cc5OC)N(C)[C@H]7[C@](O)([C@H](O)[C@]8(CC)C=CCN9CC[C@]67[C@H]89)C(=O)N)C1.OS(=O)(=O)O

Toxicity

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
mouse LD50 intraperitoneal 3500ug/kg (3.5mg/kg) KIDNEY, URETER, AND BLADDER: URINE VOLUME INCREASED

GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA"

BEHAVIORAL: ATAXIA
Kiso to Rinsho. Clinical Report. Vol. 17, Pg. 1549, 1983.
mouse LD50 intravenous 6300ug/kg (6.3mg/kg)   Journal of Toxicology and Environmental Health. Vol. 1, Pg. 843, 1976.
mouse LD50 subcutaneous 6800ug/kg (6.8mg/kg)   Kiso to Rinsho. Clinical Report. Vol. 17, Pg. 1549, 1983.
rat LD50 intraperitoneal 1050ug/kg (1.05mg/kg) KIDNEY, URETER, AND BLADDER: URINE VOLUME INCREASED

BEHAVIORAL: ATAXIA

GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA"
Kiso to Rinsho. Clinical Report. Vol. 17, Pg. 1549, 1983.
rat LD50 intravenous 1920ug/kg (1.92mg/kg) BLOOD: NORMOCYTIC ANEMIA

GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA"

KIDNEY, URETER, AND BLADDER: URINE VOLUME INCREASED
Kiso to Rinsho. Clinical Report. Vol. 17, Pg. 1549, 1983.
rat LD50 subcutaneous 1790ug/kg (1.79mg/kg)   Kiso to Rinsho. Clinical Report. Vol. 17, Pg. 1549, 1983.